TOKYO, JAPAN - July 9, 2018 - Terumo Corporation (TSE: 4543) today announced that it will construct an additional production facility for pre-filled syringes at the headquarters plant at Terumo Yamaguchi D&D Corporation, a Terumo subsidiary. The capital investment for the project will total approximately 7 billion yen. Construction is to begin in August 2018, and the facility is expected to go into operation in April 2021. This additional production facility will increase the production capacity at Terumo Yamaguchi D&D by approximately two-fold.
Yamaguchi City and Terumo Yamaguchi D&D Corporation held a signing ceremony today for the capital investment agreement.
Terumo Yamaguchi D&D Corporation operates a plant that produces Drug and Device products, which combine a medical devices and a drug in a single product. The plant is scheduled to formulate pharmaceutical products such as Humira® biosimilar (development no. FKB327, generic name: adalimumab), which is currently being reviewed for marketing approval in Europe.
Terumo Corporation will continue expanding its alliance business with pharmaceutical companies using the materials technologies and aseptic filling technology it gains from the manufacture of pre-filled syringes.
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.